CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. Its products include potassium clavulanate, cyclosporine, tacrolimus, demeclocycline hydrochloride, rifampicin, rifampicin SV sodium, teicoplanin, vancomycin HCL, fumagillin, diquafosol sodium, everolimus, daptomycin, tenofovir disoproxil aspartate, and acarbose. The company was founded on November 12, 2001 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company